The ratings of seven Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Discovery Laboratories’ (NASDAQ:DSCO) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, DSCO also gets F’s. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock.
The rating of Achillion (NASDAQ:ACHN) slips from C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. The stock price has fallen 8.2% over the past month, worse than the 3% increase the Nasdaq has seen over the same period of time. As of March 6, 2013, 16.2% of outstanding Achillion shares were held short. For more information, get Portfolio Grader’s complete analysis of ACHN stock.
Genomic Health (NASDAQ:GHDX) is having a tough week. The company’s rating falls from C to a D. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The stock also gets an F in Earnings Revisions. The stock’s trailing PE Ratio is 115.00. For a full analysis of GHDX stock, visit Portfolio Grader.
Acorda Therapeutics (NASDAQ:ACOR) experiences a ratings drop this week, going from last week’s C to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock.
Slipping from C to a D rating, Amarin (NASDAQ:AMRN) takes a hit this week. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock receives F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. Investors seem to agree with the downgrade and have pushed down the share price 8.5% over the past month. As of March 6, 2013, 16% of outstanding Amarin shares were held short. For more information, get Portfolio Grader’s complete analysis of AMRN stock.
Exelixis (NASDAQ:EXEL) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. Wall Street appears to agree with the stock downgrade, with share prices dropping 5.2% over the past month. As of March 6, 2013, 20.3% of outstanding Exelixis shares were held short. For a full analysis of EXEL stock, visit Portfolio Grader.
Trius Therapeutics (NASDAQ:TSRX) earns a D this week, falling from last week’s grade of C. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.